Merck & Co. (MRK)
(Delayed Data from NYSE)
$125.54 USD
+1.01 (0.81%)
Updated May 31, 2024 04:00 PM ET
After-Market: $125.74 +0.20 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRK 125.54 +1.01(0.81%)
Will MRK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRK
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Other News for MRK
BioNTech/ Genmab lung cancer therapy improves survival with Keytruda
Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Merck & Company (MRK)
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)
Summit lead asset approved in China for lung cancer
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results